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ABSTRACT
Introduction. Providing balanced information that emphasizes
clinical equipoise (i.e., uncertainty regarding the relative merits
of trial interventions) and exploring patient treatment prefer-
ences can improve informed consent and trial recruitment.
Within a trial comparing adjuvant radiotherapy versus active
monitoring following surgical resection for an atypical meningi-
oma (ROAM/EORTC-1308), we explored patterns in communica-
tion and reasons why health practitioners may find it challenging
to convey equipoise and explore treatment preferences.
Materials and Methods. Qualitative study embedded within
ROAM/EORTC-1308. Data were collected on 40 patients and
18 practitioners from 13 U.K. sites, including audio recordings
of 39 patients’ trial consultations, 23 patient interviews, and
18 practitioner interviews. Qualitative analysis drew on argu-
mentation theory.
Results. Practitioners acknowledged the importance of the
research question that the trial aimed to answer. However,
they often demonstrated a lack of equipoise in consultations,
particularly with eligible patients who practitioners believed
to be susceptible to side effects (e.g., cognitive impairment)
or inconvenienced by radiotherapy. Practitioners elicited but
rarely explored patient treatment preferences, especially if a
patient expressed an initial preference for active monitoring.
Concerns about coercing patients, loss of practitioner agency,
and time constraints influenced communication in ways that
were loaded against trial participation.
Conclusions. We identified several challenges that practi-
tioners face in conveying equipoise and exploring patient
treatment preferences in oncology, and particularly neuro-
oncology, trials with distinct management pathways. The find-
ings informed communication about ROAM/EORTC-1308 and
will be relevant to enhancing trial communication in future
oncology trials. Qualitative studies embedded within trials
can address difficulties with communication, thus improving
informed consent and recruitment. ROAM/EORTC-1308 RCT:
ISRCTN71502099. The Oncologist 2020;25:e691–e700
Implications for Practice: Oncology trials can be challenging to recruit to, especially those that compare treatment versus moni-
toring. Conveying clinical equipoise and exploring patient treatment preferences can enhance recruitment and patient understand-
ing. This study focused on the challenges that practitioners encounter in trying to use such communication strategies and how
practitioners may inadvertently impede patient recruitment and informed decision making. This article provides recommendations
to support practitioners in balancing the content and presentation of trial management pathways. The results can inform training
to optimize communication, especially for neuro-oncology trials and trials comparing markedly different management pathways.
INTRODUCTION
Randomized controlled trials frequently struggle to recruit
adequate numbers of eligible patients [1, 2]. Poor recruitment
can compromise a trial’s statistical power and generalizability
[3], deny or delay the benefits of health research for future
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patients [4], and increase financial costs [1, 2]. Patient under-
standing and acceptance of trial components and principles
that directly affect their care is also fundamental to recruit-
ment and informed consent [5].
Recruitment into trials that include markedly different
management pathways can be particularly challenging
because of patient and practitioner treatment preferences
[6]. A common preventable reason for poor trial recruitment
is the absence of “clinical equipoise” among health practi-
tioners [7], where clinical equipoise is defined as uncertainty
about the relative clinical merits of the intervention arms in
a trial [8]. Practitioners may knowingly or unknowingly com-
municate positive or negative beliefs about the effectiveness
or safety of either treatments being investigated, which can
undermine patient willingness to be randomized [9].
Patients may also have unfounded beliefs about trial
treatments that can deter them from participating or lead
to suboptimally informed decision making. Exploring
patient treatment preferences during trial consultations is
advocated as a way to improve patient decision making
and avoid unfounded beliefs about treatments deterring
them from being randomized [10, 11]. It entails eliciting
and acknowledging the reasons that underlie treatment
preferences, providing information to balance preferences
and address any misapprehensions, and emphasizing the
importance of keeping an open mind about trial treat-
ments [11].
Qualitative studies have been embedded in trials to iden-
tify and address recruitment challenges [12–17]. These stud-
ies examine how practitioners communicate about trials,
before providing tailored feedback to support them in opti-
mizing informed consent discussions and recruitment [18].
Previous qualitative studies have identified communication
issues in trials and supported practitioners to balance the
content and presentation of information on trial treatments,
to emphasize clinical equipoise, and optimize informed con-
sent and recruitment [19]. Such studies advocate that trial
practitioners should present equipoise convincingly [19] and
explore treatment preferences with patients [10, 11].
The Radiation versus Observation for Atypical Meningi-
oma (ROAM/EORTC-1308) trial compares adjuvant radiother-
apy with active monitoring following complete surgical
resection of an atypical meningioma [20]. As the trial com-
pares two markedly different management pathways—active
treatment (radiotherapy) to nonactive treatment (active
monitoring)—we anticipated that recruitment would be chal-
lenging. It is currently unclear whether practitioners rec-
ruiting to oncology trials, such as ROAM/EORTC-1308, are
adopting trial communication strategies advocated in the lit-
erature and what the challenges are in doing so. This qualita-
tive study embedded in ROAM/EORTC-1308 examined how
practitioners conveyed equipoise, how they explored and
responded to patient treatment preferences, and the chal-
lenges they encountered. As part of the study we provided
practitioners with feedback as the trial was ongoing in order
to enhance their communication and thereby optimize
informed consent and recruitment. The analyses we report
here describe practitioners’ communication about the trial,




The design of ROAM/EORTC-1308 and the embedded qualita-
tive study is summarized in Figure 1. Briefly, it is an ongoing
multicenter, international trial, recruiting patients who have
undergone gross total resection of intracranial atypical menin-
gioma and randomizing them to either active monitoring with
magnetic resonance imaging (MRI) or 6 weeks of adjuvant
radiotherapy (60 Gy in 30 fractions). The trial hypothesis is that
adjuvant radiotherapy reduces the risk of meningioma recur-
rence compared with active monitoring. The primary outcome
is time to MRI evidence of tumor recurrence (i.e., progression-
free survival), and secondary outcomes include toxicity of radio-
therapy, quality of life, neurocognitive function, time to second
Figure 1. Summary of the design of ROAM/EORTC-1308 and
the embedded qualitative study.
Abbreviations: MRI, magnetic resonance imaging; QoL, quality
of life.
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line treatment, time to death, and incremental cost per quality-
adjusted life year gained [20].
We used established qualitative methodology [18, 21]
to analyze trial consultation recordings and semistructured
interviews with patients and practitioners. Additionally, we
used findings from the ongoing analysis of these data to
inform feedback to practitioners (delivered via written sum-
maries tailored to individual practitioners, two U.K.-based and
one European workshop, one U.K. and Europe webinar, and a
“hints and tips” feedback sheet distributed to all trial sites) to
help them enhance their communication, although we did not
formally evaluate the impact of this feedback. A U.K. National
Research Ethics Service Committee (15/NE/0013) approved
ROAM/EORTC-1308 and the embedded qualitative study.
Setting and Participants
ROAM/EORTC-1308 opened in April 2016. Recruitment is
ongoing in 49 sites across the U.K., Europe, and Australia.
The qualitative study was conducted in 13 of 20 U.K. sites
and ran from April 2016 to November 2018. Practitioners
(neurosurgeons, radiation oncologists, and research nurses)
invited eligible patients to participate in ROAM/EORTC-
1308 typically 2–5 weeks after surgery. Patients eligible for
ROAM/EORTC-1308 were also eligible for the qualitative
study; they could participate in the trial, the qualitative
study, both, or neither. Patients and practitioners who par-
ticipated in the qualitative study agreed for their trial con-
sultation to be recorded or completed an interview, or
both. Our purposive sampling strategy aimed for diversity
in patient age, gender, socio-economic status, hospital site,
and practitioner role and to include patients who declined
ROAM/EORTC-1308 and those who consented.
Procedure
Consultation Recordings
Patients attended clinic consultations at which practitioners
typically explained the meningioma pathology results before
discussing ROAM/EORTC-1308. Practitioners requested the
permission of patients to audio record the trial consultation
and, if the patient agreed, obtained written consent at the
end of the consultation. Some patients who expressed an
interest in ROAM/EORTC-1308 were invited to attend a sec-
ond consultation, which was also audio recorded where possi-
ble. Research nurses forwarded copies of the qualitative study
consent form to the study researcher (F.C.S.) and uploaded
consultation recordings via a secure electronic facility.
Patient and Health Professional Interviews
F.C.S. (a qualitative researcher with a background in health
research) conducted and audio recorded semistructured inter-
views with patients and practitioners, either face-to-face or by
telephone, after first obtaining their consent. Interviews were
topic guided (supplemental online Appendix A) but adapted
over the course of the analysis to explore relevant issues.
Table 1 summarizes the topics explored in the patient and
practitioner interviews. Where an audio-recorded trial consul-
tation was available, F.C.S. reviewed this before the interview
to tailor questions to participants and explore pertinent aspects
of communication.
Qualitative Analysis
All consultation recordings and interviews were transcribed and
anonymized. Data collection continued until data saturation
was reached, the point at which new themes ceased being
identified [22]. Data analysis was generally interpretive and plu-
ralistic, drawing on thematic analysis [23] and the framework
approach [24]. Analysis of consultations was informed by argu-
mentation theory [25], whereby we examined the content of
arguments made by practitioners in informing patients and the
arguments made by patients in justifying their preferences. This
allowed us to identify patterns in communication relevant to
clinical equipoise and treatment preferences (see example anal-
ysis excerpt from one consultation in Table 2). Although this ini-
tially involved F.C.S. focusing on segments of consultation text
and comparing these within and between transcripts, we also
examined the data more holistically to make sure our interpre-
tations of the segments fitted with the consultation as a whole.
F.C.S. also listened to audio recordings of consultations to take
account of subtleties such as the tone and pace of speech.
Informed by the analysis of the consultations, we ana-
lyzed the patient interviews and practitioner interviews the-
matically. In cases in which we had an audio-recorded trial
consultation and an associated patient and/or practitioner
interview, we conducted integrative within-case analysis [26].
This involved drawing on themes arising from the consulta-
tions to produce narratives for each case describing how
patients and practitioners viewed and responded to commu-
nication in consultations, and thereby linking the analysis of
the consultations and interviews.
F.C.S. led all aspects of the analysis, with S.L.B. and
B.Y. also reading a subset of transcripts and meeting
Table 1. Overview of the topics explored in the patient and
health professional interviews
Patient interviews
Experience of diagnosis, surgery, and recovery
Initial thoughts about ROAM/EORTC-1308
Experience of being approached about ROAM/EORTC-1308
Thoughts on how it was explained
How the health professional explained the treatment
options and preferences
Messages that resonated about ROAM/EORTC-1308
Views and understanding of randomisation
Reasons for consent or decline
Reflections on ROAM/EORTC-1308 since being approached
Health professional interviews
Initial thoughts about ROAM/EORTC-1308
Knowledge and awareness of ROAM/EORTC-1308
Patient pathways in and outside of ROAM/EORTC-1308
Experiences of approaching patients about ROAM/
EORTC-1308
Health professional treatment preferences
Experience of delivering the treatments in and outside
ROAM/EORTC-1308
Anticipated ROAM/EORTC-1308 results
Preferences for communication feedback
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periodically with F.C.S. to develop and refine the analysis.
QSR Nvivo 11 [27] was used to organize the data set and
assist the analysis process. Illustrative quotes from the
results are listed in Tables 3 and 4, with associated quote
identifiers (e.g., Q1) listed in the results.
RESULTS
Participants’ and Qualitative Data Set Characteristics
Table 5 summarizes key participant and data set characteristics.
Data were collected on 40 patients and 18 practitioners from
13 U.K. sites. These comprised 43 audio-recorded trial consul-
tations (37 initial and 6 subsequent consultations) collected
from 39 patients, and 18 practitioner and 23 patient inter-
views. For 22 of 40 patients, we captured all three linked data
types: trial consultation, patient interview, and associated prac-
titioner interview. Of the 18 practitioners interviewed, 11 had
at least one recorded trial consultation. Most patients were
female (n = 23, 58%), and median age was 57 years (range,
29–78). Of those recruited from England (n = 35), 26% (n = 9)
were from the most deprived areas, 37% (n = 13) were from
areas of average deprivation, and 37% were from the least
deprived areas (n = 13). The overall consent rate to ROAM/
EORTC-1308 at the time of writing is 28%. Of the patients who
participated in the qualitative study, approximately half also
participated in ROAM/EORTC-1308 (n = 19/40, 48%).
Qualitative Results
Patterns in Conveying Clinical Equipoise
In consultations, all practitioners emphasized clinical equi-
poise by describing the lack of evidence and the uncertainty
as to whether patients should be actively monitored or
receive radiotherapy following surgery (Table 3, Q1). They
often presented ROAM/EORTC-1308 as an opportunity for
patients to receive additional care, regardless of the treat-
ment to which they were allocated (Q2). Some patients
described this as a motivation for participating.





initiated by Example quote
Radiotherapy might reduce risk of
meningioma recurrence
For Health professional “Sometimes we have used radiotherapy in
the thought that that would help.”
Radiotherapy has side effects Against Health professional “Radiotherapy is a treatment that has side
effects… it can make you feel a bit
headache-y… you would lose a bit more
hair in the areas that we treat.”
We don’t have evidence to say
radiotherapy will work
Both Health professional “But we’ve not got definite evidence that
radiotherapy works to keep it away.”
You’ll receive excellent support in the trial For Health professional “So either way you’re going to be closely
monitored and either way you’re gonna
get regular scans.”
You will help us to inform future
treatment
For Health professional “It’s just trying to help us answer the
question about how much benefit
radiotherapy gives now versus having it at
a later date.”
I would prefer to have radiotherapy now For Patient “So to just be monitored and see if does
comes back, then six months down the
line to have to… that’s not what I really
want.”
It would be unethical to offer radiotherapy
outside the trial
Both Health professional “We don’t tend to offer radiotherapy up
front if they’re not in the trial because we
don’t think there’s a proven benefit. So for
me to offer it outside the trial would be, I
think, not ethical.”
If you’re interested in radiotherapy, you
should consider the trial
For Health professional “I think if you were interested in
exploring, having radiotherapy at all, then
I think you should have a think about the
trial and whether you want to go into it.”
The trial might be too much for you Against Health professional “If you think that with everything you’ve
had going on… that the trial is a bit too
much for you… then we would say, we
could draw a line…”
Active monitoring is your best option
outside of the trial
Against Health professional “[The tumor is] all out and the risk of
recurrence is less than half, so we would
feel that your best bet is to have a very
close observation…”
You need time to think before you decide Against or
unclear
Health professional “You don’t have to make a decision
today… if you’re even just wanting to
consider it and go away and have a
think…”
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However, as consultations progressed, practitioners de-
scribed the treatment arms in ways that were unbalanced,
indicating that they lacked equipoise. They regularly empha-
sized the risks of radiotherapy, giving details of potential
side effects such as fatigue, hair loss (Q3), and cognitive
impairment (Q4), and its inconveniences, such as travel or
delay in returning to normal routine (Q5). Although some
elaborated on the potential effect of radiotherapy in
preventing meningioma regrowth, most only mentioned it
briefly and focused on the side effects. Furthermore, the
nature and degree of side effects were often not discussed,
leading some patients to assume side effects were severe.
Simultaneously, many practitioners neglected details about
the process and risks of active monitoring (Q6). In a context
in which active monitoring was typically the standard treat-
ment pathway outside the trial at most sites, the pattern of
Table 3. Quotes to illustrate patterns and barriers in conveying equipoise
Quote
no. Patterns in conveying equipoise
Q1 “We have two treatment options, active monitoring versus radiotherapy. We don’t know which is best and we’re
doing a trial, a study, to work out with patients which is the best treatment.” (Cons_Decline14_Neurosurgeon1)
Q2 “If you go into the trial, whichever arm you are in… you would be followed closely with scans, we’d keep a close eye
on you, we’d do some extra tests for your sort of brain function and things like that.”
(Cons_Consent2_Neurosurgeon1)
Q3 “It causes, in the short term, some additional fatigue, maybe feeling a bit headachy, and you lose your hair in the
areas that we treat.” (Cons_Decline28_Radiation-oncologist2)
Q4 “And more what we’re concerned about is the longer-term side-effects of radiotherapy, so it can affect your cognitive
function.” (Cons_Decline27_Radiation-oncologist3)
Q5 “[Radiotherapy] is an everyday treatment for around six weeks … got to admit it’s efforts on your behalf to… I think
the travelling is as much a bother than anything else.” (Cons_Consent31_Radiation-oncologist4)
Q6 “The general UK practice and also internationally a lot, is that if the tumour’s been macroscopically removed…if it’s all
visible bits have been taken out, often people will elect for a period of surveillance and then wait for the tumour…to
come back and then have radiotherapy. So this trial is really trying to answer that question. Is it, in fact, better to have
up-front radiotherapy or to have a period of surveillance.” (Cons_Decline27_Radiation-oncologist3)
Q7 “What is active monitoring? What does that entail? … when my surgeon told me … I thought the one option was just
radiotherapy, if not, being left to it.” (Int_Decline12)
Q8 “If you are going to have the radiotherapy… it can have some side effects, especially in people like you, that you’re
young, radiotherapy can affect certain parts of the brain.” (Cons_Decline_Neurosurgeon7)
Q9 “And the other thing you need to factor in is your age… because you are older, you have less, you know, you haven’t
got as many years to live as if you were 40.” (Cons_Decline4_Neurosurgeon1)
Q10 “The other thing you’d have to think about… is the fact that you live in [2 hours away] [laughter].”
(Cons_Neurosurgeon1) “Yes, it’s a long way to come… I would just probably rent something.” (Cons_Consent5)
Practitioners’ barriers to conveying equipoise
Q11 “I think the very young are difficult and also the very old who would struggle with radiotherapy. So it’s always the
extremes of age that are a bit more tricky, but otherwise there’s a big, big trench in the middle we should be able to
hopefully hone in on… Once you’re up above your mid 70s then… radiotherapy isn’t an easy option unless you’re very
fit.” (Int_Radiation-oncologist5)
Q12 “I think it will affect like higher cognitive functions. If somebody obviously works in a highly skilled professional, you
know. It depends also on the pre-morbid status and it depends on what expectations are from him professionally or
socially, because in some people it may not be very obvious but in others it will be more obvious… that is a stumbling
block I think for the study.” (Int_Neurosurgeon7)
Q13 “Certainly if there’s no brain invasion, then surveillance [monitoring] is appropriate… if it’s a standard tumour then I
would say that surveillance is appropriate… This trial is using quite a high dose of radiotherapy. Sometimes with grade
two we know historically it’s the lower dose but for this study, ’cause there is evidence for it in other studies that it’s
acceptable, they’ve used the higher dose of radiotherapy.” (Int_Radiation-oncologist8)
Q14 “It’s back to the fact that if you’re offering a treatment up front you need to discuss all the side effects of the
treatment and because you’re offering, you’re basically offering a treatment against what could be perceived as a no
treatment option… what you’re then talking about from the negative point of view are the things that will actually,
could potentially be an issue for patients if they are randomised to the radiotherapy arm.” (Int_Radiation-oncologist6).
Q15 “When [practitioners’ are] talking about treatments they have to point out the potential side effects… these days
everybody’s so keen about covering their backs.” (Int_ResearchNurse9)
Q16 “Personally I think [radiotherapy side effects are discussed in detail] because [practitioners] want, they don’t want
anyone to complain back, saying, ‘this happened to me and is it because of radiotherapy?’” (Int_ResearchNurse10)
Q17 “Radiotherapy does have side effects and we’ve got to be honest about that… And, you know, I see a lot of people
after radiotherapy, some are fine but a lot have ongoing side effects and, you know. So I would still want, I wouldn’t
want my role to be taken away. I would still want to be, because I feel I’m the, the patient advocate as it were… I’m
not there to sell a trial to somebody that I don’t think wants it.” (Int_Neurosurgeon11)
Date type: consultation = Cons, Interview = Int; patient’s trial participation status: consent, decline; practitioner role: neurosurgeon, oncologist
(radiation oncologist), research nurse; patients and practitioners have been allocated an identification number (e.g., Decline23).
© 2020 The Authors.
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emphasizing the drawbacks of radiotherapy, but not its
potential benefits, and neglecting the drawbacks of active
monitoring, was, in effect, an argument against participating
in ROAM/EORTC-1308. We found that patients, when inter-
viewed, were particularly confused about the monitoring
arm, and some were unaware that ROAM/EORTC-1308 had
two treatment arms (Q7). Although the patient information
sheet referred to “active monitoring” to label this arm,
and this term was also recommended in feedback
to practitioners, practitioners often used terms such as,
Table 4. Quotes to illustrate patterns and barriers to exploring patients’ treatment preferences
Quote
no. Patterns in exploring patients’ treatment preferences
Q18 “Do you have a thought either way? I know when you first came you were like can I have radiotherapy?”
(Cons_Consent22_Neurosurgeon1)
Q19 “Do you have any questions about either way to go?” (Cons_Decline30_Radiation-oncologist6)
Q20 “The more I’m swinging more towards surveillance rather than radiotherapy… but I understand the need for research
and anything that will reduce recurrence, you know.” (Cons_ Consent22); “…There are obviously advantages and
disadvantages of the therapy. The, if you’re in a study and randomised to radiotherapy, the potential advantage is that
it reduces the risk of regrowth but there is a potential, you know, a potential risk of side effects, as we discussed.”
(Cons_Neurosurgeon1)
Q21 “To be honest with you, I’ve made my decision [not to take part]…. because of the timeline of my holiday and coming
back to work.” (Cons_Consent25) … “When is your holiday? … Okay, right. So we have until… until [date] to start you,
‘cause we have 12 weeks… As far as going back to work is concerned, I would certainly have thought that there would
be no reason, if we put the sort of timescale that you’re looking at anyway.” (Cons_Radiation-oncologist6)
Q22 “To just be monitored and see if [the tumour] does comes back, then six months down the line to have to… that’s not
what I really want.” (Cons_Consent6) “… the reality is that the risk of it coming back is only about three or four out of
ten, so it’s still more likely that it won’t… And even with radiotherapy, there’s no guarantee that you wouldn’t be any
better… I think our default, given that we don’t know, is we don’t tend to offer radiotherapy up front if they’re not in
the trial because we don’t think there’s a proven benefit.” (Cons_Radiation-oncologist2)
Q23 “I do want to go ahead with it [the trial] … I want to do whatever is going to get rid of it …” (Cons_Decline12); “Well I
think the first thing to say that it has been got rid of in the sense that what was there [the surgeon] has done a
fantastic resection… what we would offer you today, because one is to consider entry into the trial… and then if you, if
you decided you didn’t want to go into the trial I think, being the age that you are, probably our best option would be
to survey you in the first instance.” (Cons_Radiation-oncologist5)
Q24 “I’m [older age] this year… and I just think to myself, you know, it’s took a long while for it to grow hasn’t it? … And
this is in the back of my mind, you know, whether to proceed with the other ongoing thing what you’ve just told me
about.” (Cons_ Decline17); “Yeah. I mean I think it’s fair to say that the chances of, you know, you running into further
problems from this I think are hopefully quite small.” (Cons_Radiation-oncologist2)
Q25 “I’m quite… well the thing is I’m quite happy like, you know, [other surgeon] said… they’ve tried and… most of the
tumour is taken out now…” (Cons_Decline26) “Absolutely, that is the most important thing… and you’re so well so I
think… because you are so young and the main question is people like you, we don’t know what the future holds and
what is the best thing and want to give the best to our patients, so have a little think about it…”
(Cons_Neurosurgeon7)
Practitioners’ barriers to exploring patients’ treatment preferences
Q26 “If a patient says, oh no, no, I don’t want radiotherapy my aunt had that. I would always ask them, you know, what did
your aunt have treated, when was it, how long ago, what side effects did they have, that your treatment is going to be
very different because we’re treating the brain and we’ve got modern radiotherapy… Whatever they say you’ve got to
get more detail, you can’t just accept it at face value that they’re saying there’s a problem with the treatment.”
(Int_Radiation-oncologist12)
Q27 “We have to be very, very careful we’re not coercing people to do something that they’re not keen to do… So if a
patient says I’m not interested in it, then I can’t say, ‘I know you say that but I think you should think about’, I think
that would be seen as coercion.” (Int_Radiation-oncologist12)
Q28 “The GP advised them not to participate in the study… but then I was like, you know, you don’t really want to push
patients, so yeah, I was like, okay that’s fine, I respect that…” (Int_Neurosurgeon13)
Q29 “I don’t like specifically ask the question, which treatment you would prefer… because generally people are coming to
see me for me to, as me as the expert to kind of outline the options… They’re sort of coming to me because they
want answers to their diagnosis.” (Int_Radiation-oncologist3)
Q30 “I would think that, if clinicians aren’t doing that [exploring treatment preferences], then it suggests that they’re trying
to get through the consultation quickly.” (Int_Radiation-oncologist12)
Q31 “Maybe time pressure [is a reason why practitioners might not explore treatment preferences]… I think that’s always a
factor, isn’t it, in the NHS.” (Int_Radiation-oncologist14)
Q32 “We’re all under pressure, we can’t be spending two hours with somebody who we know that is never going to… you
know, even consider participation. So perhaps that’s the reason why [practitioners don’t spend time exploring patient
treatment preferences with all patients]… it just makes sense really, rather than to keep pushing.”
(Int_Radiation-oncologist3)
Date type: Consultation = Cons, Interview = Int; patient trial participation status: consent, decline; practitioner role: neurosurgeon, oncologist
(radiation oncologist), research nurse; patients and practitioners have been allocated an identification number (e.g., Decline23).
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“observation,” “surveillance,” and “watch and wait,” which
can have negative connotations for patients.
Practitioners often personalized their statements about
the risks of radiotherapy to individual patients. For example,
in consultations with younger patients, some practitioners
commented that the risk of cognitive impairment from radio-
therapy was greater for younger patients (Q8). Similarly, in
consultations with older patients, some practitioners com-
mented that the benefits of radiotherapy might be negligible
for older patients (Q9). When subsequently interviewed, such
patients often indicated that these personalized arguments
were highly salient and deterred them from participating.
Practitioners also highlighted personalized inconveniences
(e.g., travel) in consultations before patients had themselves
identified it as important in their decision making (Q10).
Reasons Why Practitioners Do Not Convey Clinical
Equipoise
When interviewed, practitioners acknowledged the impor-
tance of the ROAM/EORTC-1308 research question, but they
also described personal views about radiotherapy that corrob-
orated the patterns of imbalanced trial communication we
observed in consultations. They described concerns about
treating patients toward the younger end of the age spectrum
with radiotherapy because such patients had more years to
live with any adverse cognitive sequelae. Conversely, they
described concerns about treating patients toward the older
end of the age spectrum with radiotherapy because older
patients had relatively fewer years of life during which menin-
gioma regrowth could occur and because they might struggle
to tolerate radiotherapy (Q11). When interviewed, some prac-
titioners voiced more idiosyncratic views against radiotherapy:
one commented that radiotherapy was less suited to patients
who had “highly skilled” occupations because the impact on
their cognitive functioning would be more pronounced (Q12),
whereas another was concerned that the radiation dose deliv-
ered in ROAM/EORTC-1308 was higher than that which they
would deliver outside the trial (Q13).
Practitioners acknowledged when interviewed that they
provided patients with more information about radiother-
apy than active monitoring but commented that it was
essential to comprehensively describe the risks of radiother-
apy, as patients would typically receive active monitoring
outside of the trial (Q14). They also indicated that there
could be ramifications for them personally if a patient sub-
sequently complained about a side effect of radiotherapy
that had not been detailed (Q15, Q16). Some practitioners
commented that the trial diminished their clinical agency
and they had a duty of care to provide patients with details
of treatment risks, despite the lack of robust evidence on
frequency and magnitude of these risks (Q17).
Patterns in Exploring Patient Treatment Preferences
In line with consultation feedback over the course of ROAM/
EORTC-1308, practitioners increasingly elicited patient treat-
ment preferences (Table 4, Q18, Q19). Although it was rare,
a few practitioners acknowledged patients’ reasons for their
preferences and provided information to balance patients’
views of each arm to emphasize equipoise (Q20). Occasion-
ally, practitioners responded to allay patient concerns about
the process or inconvenience of radiotherapy. For example,
when a patient indicated a preference for active monitoring
during one consultation, the practitioner responded by
exploring the patient’s underlying reason for the preference.
This identified that the patient had an unfounded concern
Table 5. Summary of participant and data characteristics
Participant characteristics n
Patient participant characteristics overall (n = 40)
Median age (range) 57 (29–78)
Gender, females (vs. males) 23 (17)
Index of multiple deprivation decilea
Most deprived (1–3) 9
Average deprivation (4–7) 13
Least deprived (8–10) 13
Trial participation status, consent (vs.
declined)
19 (21)
Trial consultation recorded, yes (vs. no) 39 (1)
Patient interviewed, yes (vs. no) 23 (17)
Patient’s health professional interviewed,b
yes (vs. no)
37 (3)
No. of participating NHS sites
England 7
Scotland 1
Patients with recorded trial consultations (n = 39)
Consultation type
Initial consultation recorded 37
Subsequent consultations recorded 6
Consultation duration
Initial consultation median (range), min 19 (6–50)
Second consultation median (range), min 9 (3–41)
Patients interviewed (n = 23)
Median interview duration (range), min 61 (32–102)
Format of interview, face-to-face (vs.
telephone)
10 (13)
Practitioners interviewed (n = 18)





Format of interview, face-to-face (vs.
telephone)
5 (13)
No. of participating NHS sites
England 11
Scotland 0
aThe Index of Multiple Deprivation ranks every small area in
England from 1 (most deprived area) to 32,844 (least deprived
area) but are not available for other regions of the U.K. The dec-
iles are derived from the ranks and we divided these into most
deprived (1–3), average deprivation (4–7), and least
deprived (8–10).
bNeurosurgeon, radiation oncologist, or research nurse present in
the consultation; chronological order of consultation and health
professional interview varied.
Abbreviation: NHS, National Health Services.
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that radiotherapy would delay their return to work. The
practitioner’s response regarding when and how radiother-
apy could be delivered helped to allay the patient’s concern,
enabling them to participate without reservation (Q21).
More commonly, when patients voiced an interest in par-
ticipating in ROAM/EORTC-1308, practitioners prompted
them to consider the possible downsides of radiotherapy
(Q22, Q23), but they did not similarly prompt patients who
expressed a preference for active monitoring (Q24, Q25) to
consider the downsides of this management pathway. In this
way, practitioners’ communication was loaded against radio-
therapy and in favor of active monitoring. In effect, this
worked against participation in ROAM/EORTC-1308 because
active monitoring was typically the standard treatment out-
side the trial in most sites.
Reasons Why Practitioners Do Not Explore Patient
Treatment Preferences
Whereas some practitioners felt that exploring patient treat-
ment preference was beneficial to discover patients’ precon-
ceptions and address misconceptions (Q26), others feared
that exploring treatment preferences could be viewed as tan-
tamount to coercing patients to participate in ROAM/EORTC-
1308 (Q27). Some patients were also advised by practitioners
outside of the trial (including neurosurgeons and family doc-
tors) not to participate. Some worried that exploring patient
treatment preferences when these had been informed by dis-
cussions with other practitioners could also be viewed as
coercive (Q28). Two practitioners suggested that exploring
treatment preferences conflicted with patient expectations of
a practitioner’s role, which they felt was to advise patients on
which treatments were best for them (Q29). Practitioners
alluded to time limitations during consultations as a barrier to
exploring treatment preferences (Q30, Q31). Some suggested
that it would be a poor use of time to explore treatment pref-
erences with patients who appeared disinterested in the trial,
as they were unlikely to participate (Q32).
DISCUSSION
This is the first study to examine how practitioners convey
equipoise and respond to patient treatment preferences in
a neuro-oncology trial, like ROAM/EORTC-1308 [20], that
compares markedly different management pathways. We
anticipated that some practitioners might lack clinical equi-
poise and that this could influence their communication
with patients and impede informed consent discussions and
trial recruitment [6]. In keeping with previous studies, prac-
titioners expressed support for the trial question, but in
consultations, they often lacked balance in how they pres-
ented the treatment arms and responded to patient prefer-
ences [9, 28]. For example, we identified that practitioners’
responses were loaded against radiotherapy and favored
active monitoring, often in ways that were personalized to
a patient’s individual characteristics. This effectively worked
against trial participation and informed consent, particularly
as personalized risk communication is more persuasive than
generic risk communication [29].
Our study indicates that practitioners working on neuro-
oncology trials that investigate a treatment (in this case radio-
therapy) versus active monitoring face previously unreported
challenges in conveying equipoise. Treatments like radiother-
apy pose a risk of cognitive impairment, which threatens a
patient’s sense of identity [30] and which many fear more
than death [31]. This might partly explain why practitioners
spent more time detailing the risks of radiotherapy, including
cognitive impairment, than emphasizing the potential benefit
of radiotherapy in reducing meningioma recurrence. Despite
this focus on the radiotherapy risks in consultations, discus-
sion of the likely degree of any impairment and how it might
affect patients was often limited. In this lacuna, some patients
assumed the impairment would be severe. Practitioners need
to explain the potential drawbacks of both the intervention
and active monitoring arms in such trials in ways that make
sense to patients. Not doing so risks leaving patients with mis-
understandings about trial treatments that can lead to them
deciding to join or decline based on false premises [10, 32].
Figure 2 provides example arguments for and against both
management pathways that practitioners might convey and
discuss with patients to further balance ROAM/EORTC-1308
trial consultations. Conducting feasibility trials with embedded
qualitative studies helps to identify and address such issues,
enabling practitioners to optimize trial communication before
a full-scale trial [33]. Additionally, in the context of trial
Figure 2. Recommendations on key pros and cons to convey to patients regarding the management pathways in ROAM/EORTC-1308.
Abbreviation: MRI, magnetic resonance imaging.
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recruitment consultations, in which patients have been
assessed as eligible based on criteria specified in the trial pro-
tocol, we consider it advisable to avoid personalized risk com-
munication across both treatment arms.
This is the first study to identify the reasons that underlie
practitioner reluctance to explore patient treatment prefer-
ences during trial consultations more broadly. Although practi-
tioners increasingly elicited treatment preferences throughout
the course of ROAM/EORTC-1308, suggesting that the feed-
back we provided influenced their communication, they
remained reluctant to explore treatment preferences for fear
that it could be viewed as coercive. This led them to largely
accept patient treatment preferences at face value and avoid
providing information to balance preferences. This is especially
pertinent because the priorities that inform patients’ delibera-
tions about treatments are rather different to those that
inform the deliberations of oncologists and other practitioners
[34]. Practitioner reluctance to explore patient treatment pref-
erences seemed to reflect the belief that doing so is inconsis-
tent with patient voluntariness, founded on an assumption
that voluntariness depends on independent choice [35]. Yet,
exploration of patient treatment preference can be ethically
appropriate and enhance informed consent and trial recruit-
ment [10, 11]. Future practitioner training might usefully intro-
duce such ethical conceptions of autonomy as relational [35]
and consider how far preference exploration is consistent with
such conceptions. Future research should also explore patient
views on the acceptability of treatment preference exploration
to establish whether they find it supportive or coercive.
A major strength of this study was the triangulation of
findings from analysis of trial consultations and interviews
with the practitioner and patient interviews. The method of
analyzing trial consultations and practitioner interviews has
been adopted elsewhere [18] but less often accompanied by
analysis of patient interviews [36] and never previously has
such work drawn on argumentation theory. This approach
allowed us to identify patterns in trial communication, such
as practitioners’ responses to patient treatment preferences,
and in turn, identify how practitioners’ beliefs about treat-
ments undermined recruitment [9].
Qualitative studies are characterized by smaller sample
sizes, but in-depth analysis generates valuable insights [37]
that will be transferable to future oncology trials. Our patient
and health professional interview samples encompassed mul-
tiple sites and comprised a diverse sample of participants from
across the U.K. We provided ongoing feedback to practitioners
based on the ongoing data analyses to enhance their commu-
nication. Although we did not formally evaluate the impact of
this because of the rarity of atypical meningioma and infre-
quent recruitment consultations, as we note above, practi-
tioners seemed to increasingly elicit treatment preferences
over the course of the trial. As such, it is important to note
that our study is not an investigation of naturalistic communi-
cation. We also cannot rule out that being audio recorded
may have influenced communication during recruitment con-
sultations; however, research in other contexts has found little
evidence of such influence [38]. Our study focused on U.K.-
based patients and practitioners, and research in other coun-
tries is needed to explore the wider transferability of our find-
ings. We focused on communication between patients and
practitioners, yet patients’ family members play an important
supportive role and future work examining their role in
recruitment consultations may be illuminating. Furthermore,
because of the relative rarity of atypical meningioma, ROAM/
EORTC-1308 practitioners did not have regular opportunities
to hone and refine their trial communication in response to
qualitative feedback, and it was not possible to formally assess
the effect of qualitative feedback on trial communication or
recruitment rates. Nevertheless, practitioners reported that
the consultation feedback helped them to improve communi-
cation in subsequent trial consultations.
CONCLUSION
Our study adopted qualitative methods to triangulate consul-
tations and patient and practitioner interviews to explore how
practitioners communicated about an oncology trial with
widely differing management pathways. Practitioners encoun-
tered challenges in balancing the content and presentation of
treatment arms, often due to concerns that radiotherapy
might entail further burden and side effects, such as cognitive
impairment. They also described reluctance to explore patient
treatment preferences, largely due to fear of coercing patients
to participate, and time constraints in clinics. These concerns
heavily influenced the communication of practitioners in ways
that were effectively loaded against trial participation. The
results can be used to inform training to optimize oncology
trial communication, particularly neuro-oncology trials and
when trials compare markedly different treatment arms. Such
training might benefit from exploring practitioners’ views of
decision-making voluntariness and coercion by introducing
recent ethical conceptions of autonomy as relational.
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